DE69533334D1 - Spezifische krebs-immuntherapie mit rekombinantem bakteriellem impfstoff - Google Patents

Spezifische krebs-immuntherapie mit rekombinantem bakteriellem impfstoff

Info

Publication number
DE69533334D1
DE69533334D1 DE69533334T DE69533334T DE69533334D1 DE 69533334 D1 DE69533334 D1 DE 69533334D1 DE 69533334 T DE69533334 T DE 69533334T DE 69533334 T DE69533334 T DE 69533334T DE 69533334 D1 DE69533334 D1 DE 69533334D1
Authority
DE
Germany
Prior art keywords
cancer immunotherapy
recombinant bacterial
specific cancer
bacterial vaccine
listeriolysin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69533334T
Other languages
English (en)
Other versions
DE69533334T2 (de
DE69533334T3 (de
Inventor
Yvonne Paterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23315786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69533334(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of DE69533334D1 publication Critical patent/DE69533334D1/de
Publication of DE69533334T2 publication Critical patent/DE69533334T2/de
Application granted granted Critical
Publication of DE69533334T3 publication Critical patent/DE69533334T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69533334.8T 1994-11-08 1995-11-03 Impfstoff zum Auflösen einer Immunreaktion auf ein tumorspezifisches Antigen Expired - Lifetime DE69533334T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/336,372 US6051237A (en) 1994-11-08 1994-11-08 Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US336372 1994-11-08
EP95939926A EP0790835B2 (de) 1994-11-08 1995-11-03 Spezifische krebs-immuntherapie mit rekombinantem bakteriellem impfstoff
PCT/US1995/014741 WO1996014087A1 (en) 1994-11-08 1995-11-03 Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector

Publications (3)

Publication Number Publication Date
DE69533334D1 true DE69533334D1 (de) 2004-09-09
DE69533334T2 DE69533334T2 (de) 2004-12-09
DE69533334T3 DE69533334T3 (de) 2014-11-13

Family

ID=23315786

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69533334.8T Expired - Lifetime DE69533334T3 (de) 1994-11-08 1995-11-03 Impfstoff zum Auflösen einer Immunreaktion auf ein tumorspezifisches Antigen

Country Status (7)

Country Link
US (3) US6051237A (de)
EP (1) EP0790835B2 (de)
JP (2) JP3995712B2 (de)
AT (1) ATE272407T1 (de)
CA (1) CA2204666C (de)
DE (1) DE69533334T3 (de)
WO (1) WO1996014087A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8791237B2 (en) * 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US7635479B2 (en) * 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
AU749695B2 (en) * 1997-09-10 2002-07-04 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
DE19949594A1 (de) * 1999-10-14 2001-04-26 Deutsches Krebsforsch Rekombinante attenuierte Listerien zur Immuntherapie
DE19949595A1 (de) * 1999-10-14 2001-05-03 Deutsches Krebsforsch CTAGE-Genfamilie
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US6892140B1 (en) * 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
DE10208653A1 (de) * 2002-02-28 2003-09-18 Medinnova Ges Med Innovationen Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren
AU2003219983A1 (en) * 2002-03-01 2003-09-16 Applied Immune Technologies Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens
US6688989B2 (en) * 2002-04-25 2004-02-10 Acushnet Company Iron club with captive third piece
EP1513924A4 (de) * 2002-05-29 2008-05-21 Univ California Attenuierte listeria spp. und verfahren zur verwendung davon
US20090110702A1 (en) * 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) * 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
AU2004204751A1 (en) * 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
ATE552843T1 (de) * 2003-02-06 2012-04-15 Aduro Biotech Listerien deren eindringen in nicht-phagozytische zellen abgeschwächt ist, impfstoffe, die diese listerien enthalten und deren verwendungen
JP4839209B2 (ja) * 2003-02-06 2011-12-21 アンザ セラピューティクス，インコーポレイテッド 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP2007509067A (ja) * 2003-10-15 2007-04-12 メディミューン，インコーポレーテッド リステリアに基づくＥｐｈＡ２ワクチン
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US20060121053A1 (en) * 2004-10-18 2006-06-08 Pamela Sweeney High cell density process for growth of Listeria
US7935804B2 (en) * 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US20070207171A1 (en) * 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
WO2007144647A2 (en) * 2006-06-15 2007-12-21 Timothy John Mitchell Adjuvant compositions
JP2009545330A (ja) * 2006-08-04 2009-12-24 ザ トラスティーズ オブ ザ ユニバーシティー オブ ぺンシルべニア Ｉｇｅ依存性疾患を治療するための方法および組成物
DK2977456T3 (en) * 2006-08-15 2018-01-22 Univ Pennsylvania Compositions comprising HMW-MAA and fragments thereof for the treatment of cancer
US8268326B2 (en) * 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8277797B2 (en) 2006-11-22 2012-10-02 The Regents Of The University Of California Interferon-β production modulating Listeria strains and methods for using same
US9695397B2 (en) 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20110293608A1 (en) 2008-12-03 2011-12-01 The Johns Hopkins Univeristy Annexin a2 as immunological target
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
EP2403935B1 (de) 2009-03-04 2017-05-10 The Trustees Of The University Of Pennsylvania Zusammensetzungen mit angiogenen faktoren und verwendungsverfahren dafür
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9161974B2 (en) 2010-05-23 2015-10-20 Aduro Biotech, Inc. Methods and compositions using listeria for adjuvant treatment of cancer
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
ES2684684T3 (es) 2010-11-17 2018-10-04 Aduro Biotech, Inc. Métodos y composiciones para inducir una respuesta inmune al EGFRVIII
US10702614B2 (en) 2011-02-15 2020-07-07 Albert Einstein College Of Medicine Radiobacteria for therapy of cancer
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
JP2015511602A (ja) 2012-03-12 2015-04-20 アドバクシス， インコーポレイテッド リステリアワクチン処理後のサプレッサー細胞機能抑制
JP2015534822A (ja) 2012-11-06 2015-12-07 アデュロ バイオテック，インコーポレイテッド 条件的弱毒化細菌種ならびにその調製法および使用法
KR102160322B1 (ko) 2012-12-27 2020-09-25 아두로 바이오테크, 인코포레이티드 항원 서열의 리스테리아 발현을 용이하게 하는 신호 펩타이드 융합 상대 및 이의 제조방법 및 용도
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
CN106456726A (zh) 2014-02-18 2017-02-22 阿德瓦希斯公司 生物标志物导向的多靶点免疫治疗
US10293039B2 (en) 2014-04-07 2019-05-21 The Board Of Trustees Of The University Of Illinois Attenuated Listeria monocytogenes mutant as a vaccine vector for the delivery of exogeneous antigens
EP3134510B1 (de) 2014-04-24 2023-11-01 Advaxis, Inc. Rekombinante listerienimpfstoffstämme und verfahren zur herstellung davon
WO2016061115A1 (en) 2014-10-13 2016-04-21 Providence Health & Services-Oregon D/B/A Providence Portland Medical Center Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
MA44378A (fr) 2015-04-13 2019-01-23 Aduro Biotech Inc Protéines de fusion immunogènes pour le traitement du cancer
BR112017022076A2 (pt) 2015-04-13 2018-08-14 Aduro Biotech, Inc. fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas
SG11201901979SA (en) 2016-11-30 2019-04-29 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2018336988B2 (en) 2017-09-19 2023-06-22 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or Listeria strains
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN112538452A (zh) * 2020-11-26 2021-03-23 浙江农林大学 基于重组减毒单増李斯特菌的宫颈癌治疗性疫苗及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816253A (en) * 1977-12-08 1989-03-28 Likhite Vilas V Novel mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
US4567041A (en) * 1977-12-08 1986-01-28 Likhite Vilas V Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
JPS63173594A (ja) * 1986-08-29 1988-07-18 Medeisa Shinyaku Kk 発癌遺伝子により誘導される分泌タンパク質
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5830702A (en) * 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
WO1992021032A1 (en) * 1991-05-24 1992-11-26 The Regents Of The University Of California Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients
FR2686896B1 (fr) * 1992-01-31 1995-01-06 Pasteur Institut Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.
US5633234A (en) † 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5876735A (en) * 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7635479B2 (en) * 2000-03-29 2009-12-22 The Trustees Of The University Of Pennsylvania Composition and methods for enhancing immunogenecity of antigens
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP0902086A1 (de) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberkolose Impfstoff
US6818002B2 (en) * 1999-02-02 2004-11-16 Samuel Shiber Vessel cleaner and barrier
DE19949594A1 (de) * 1999-10-14 2001-04-26 Deutsches Krebsforsch Rekombinante attenuierte Listerien zur Immuntherapie
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US20060051380A1 (en) * 2002-02-06 2006-03-09 The Johns Hopkins University Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
US20060121053A1 (en) * 2004-10-18 2006-06-08 Pamela Sweeney High cell density process for growth of Listeria

Also Published As

Publication number Publication date
CA2204666C (en) 2010-01-26
DE69533334T2 (de) 2004-12-09
EP0790835A4 (de) 2000-07-26
EP0790835B1 (de) 2004-08-04
JP3995712B2 (ja) 2007-10-24
EP0790835B2 (de) 2010-06-23
EP0790835A1 (de) 1997-08-27
JP2007254485A (ja) 2007-10-04
DE69533334T3 (de) 2014-11-13
US7135188B2 (en) 2006-11-14
CA2204666A1 (en) 1996-05-17
US20030202985A1 (en) 2003-10-30
ATE272407T1 (de) 2004-08-15
US6051237A (en) 2000-04-18
WO1996014087A1 (en) 1996-05-17
US6565852B1 (en) 2003-05-20
JPH10509448A (ja) 1998-09-14

Similar Documents

Publication Publication Date Title
DE69533334D1 (de) Spezifische krebs-immuntherapie mit rekombinantem bakteriellem impfstoff
HU9500571D0 (en) Retro-, inverso-, and retro-inverso synthetic peptide analogues
EP1622648A4 (de) Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
FI924069A0 (fi) Terapeutiskt anvaendbara peptider och peptidfragment.
DE60044665D1 (de) Her2/neu fusionsproteine
FI932678A0 (fi) Pao alfavirus baserande DNA expressionssystem
EP0793717A4 (de) Orale immunisierung durch verwendung von transgenen pflanzen
DE60040651D1 (de) Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
AU3472299A (en) Rna cancer vaccine and methods for its use
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
GR3030716T3 (en) Selective system scan for multizone radiotelephone subscriber units.
WO2002074920A3 (en) A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
MXPA01003240A (es) Mamaglobina, una proteina secretada del cancer mamario especifica de mama.
AU4803785A (en) Cross-reactive and protective epitopes of circumsporozoite proteins
ES2143996T3 (es) Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.
WO2002000250A3 (en) Hiv-1 vaccines and screening methods therefor
ES8801127A1 (es) Un procedimiento para preparar una vacuna auto antigena en forma de virus modificado de la viruela vacuna.
TW221711B (en) N-AFP monoclonal antibody and method of preparation thereof

Legal Events

Date Code Title Description
8363 Opposition against the patent
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8366 Restricted maintained after opposition proceedings
8332 No legal effect for de
R073 Re-establishment requested

Ref document number: 790835

Country of ref document: EP

R073 Re-establishment requested

Ref document number: 790835

Country of ref document: EP

R074 Re-establishment allowed

Ref document number: 790835

Country of ref document: EP